Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M138,733Revenue $M11,202Net Margin (%)27.5Z-Score7.5
Enterprise Value $M142,383EPS $1.8Operating Margin %40.4F-Score7
P/E(ttm))33.5Cash Flow Per Share $4.3Pre-tax Margin (%)37.6Higher ROA y-yY
Price/Book10.410-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsN
Price/Sales11.35-y EBITDA Growth Rate %0.9Current Ratio2.2Lower Leverage y-yY
Price/Cash Flow17.4y-y EBITDA Growth Rate %86.1ROA % (ttm)13.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)27.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M1,536ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 90.3415%Add 7.91%345,320
GILDRay Dalio 2014-03-31 Add0.12%$68.55 - $83.95
($78.44)
$ 90.3415%Add 541.42%247,721
GILDGeorge Soros 2014-03-31 Buy 0.04%$68.55 - $83.95
($78.44)
$ 90.3415%New holding, 50000 sh.50,000
GILDJohn Burbank 2014-03-31 Buy 0.01%$68.55 - $83.95
($78.44)
$ 90.3415%New holding, 3619 sh.3,619
GILDMario Gabelli 2014-03-31 Add$68.55 - $83.95
($78.44)
$ 90.3415%Add 31.65%44,240
GILDDaniel Loeb 2014-03-31 Sold Out -1.9%$68.55 - $83.95
($78.44)
$ 90.3415%Sold Out0
GILDJohn Griffin 2014-03-31 Sold Out -0.48%$68.55 - $83.95
($78.44)
$ 90.3415%Sold Out0
GILDVanguard Health Care Fund 2014-03-31 Reduce-0.46%$68.55 - $83.95
($78.28)
$ 90.3415%Reduce -41.41%2,713,300
GILDJulian Robertson 2013-12-31 Add1.52%$58.9 - $75.2
($69.65)
$ 90.3430%Add 25.84%320,001
GILDDaniel Loeb 2013-12-31 Add1.27%$58.9 - $75.2
($69.65)
$ 90.3430%Add 200%1,500,000
GILDRay Dalio 2013-12-31 Buy 0.02%$58.9 - $75.2
($69.65)
$ 90.3430%New holding, 38621 sh.38,621
GILDJohn Griffin 2013-12-31 Reduce-1.02%$58.9 - $75.2
($69.65)
$ 90.3430%Reduce -68.21%620,000
GILDJohn Hussman 2013-12-31 Sold Out -0.86%$58.9 - $75.2
($69.65)
$ 90.3430%Sold Out0
GILDVanguard Health Care Fund 2013-12-31 Reduce-0.4%$58.9 - $75.2
($69.65)
$ 90.3430%Reduce -28.62%4,630,700
GILDGeorge Soros 2013-12-31 Sold Out -0.02%$58.9 - $75.2
($69.65)
$ 90.3430%Sold Out0
GILDDaniel Loeb 2013-09-30 Buy 0.79%$51.98 - $64.32
($59.85)
$ 90.3451%New holding, 500000 sh.500,000
GILDMariko Gordon 2013-09-30 Add0.01%$51.98 - $64.32
($59.85)
$ 90.3451%Add 46.84%15,934
GILDMario Gabelli 2013-09-30 Add$51.98 - $64.32
($59.85)
$ 90.3451%Add 43.6%31,305
GILDJulian Robertson 2013-09-30 Reduce-0.86%$51.98 - $64.32
($59.85)
$ 90.3451%Reduce -34.29%254,300
GILDJohn Griffin 2013-09-30 Reduce-0.61%$51.98 - $64.32
($59.85)
$ 90.3451%Reduce -33.9%1,950,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD George Soros 2014-03-3150,00000.04New Buy
GILD John Burbank 2014-03-313,61900.01New Buy
GILD Ray Dalio 2014-03-31247,7210.020.14+541.42%
GILD Mario Gabelli 2014-03-3144,24000.02+31.65%
GILD Mariko Gordon 2014-03-3118,08900.05+17.07%
GILD Julian Robertson 2014-03-31345,3200.028+7.91%
GILD Jean-Marie Eveillard 2014-03-3140000
GILD Ronald Muhlenkamp 2014-03-31192,0150.012.4-0.4%
GILD Vanguard Health Care Fund 2014-03-312,713,3000.180.54-41.41%
GILD Daniel Loeb 2014-03-31000Sold Out
GILD John Griffin 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Carter Paul RutherfordEVP Commercial Ops 2014-07-08Sell16,728$86.453.33view
Alton Gregg HEVP, Corp & Med Affairs 2014-07-01Sell33,000$84.126.19view
MARTIN JOHN CChairman and CEO 2014-07-01Sell140,625$84.845.29view
Whitley Richard JamesDirector 2014-07-01Sell5,000$83.656.79view
Washington Robin LEVP, CFO 2014-06-30Sell10,400$83.986.37view
Cogan John FrancisDirector 2014-06-23Sell5,000$81.829.18view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2014-06-16Sell90,000$80.910.42view
Carter Paul RutherfordEVP Commercial Ops 2014-06-09Sell16,728$79.4312.46view
Washington Robin LEVP, CFO 2014-06-04Sell6,426$82.528.25view
MARTIN JOHN CChairman and CEO 2014-06-02Sell140,625$81.329.85view

Press Releases about GILD :

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Why AbbVie Looks Like a Sell Jul 18 2014 
Why Gilead Sciences Will Grow to $100 Jul 18 2014 
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 
Weekly CFO Sells Highlight: Facebook Inc, Workday Inc, Gilead Sciences Inc. Jun 23 2014 
Weekly Insider Sells Highlight: FB, NFLX, WDAY, GILD Jun 22 2014 
Julian Robertson Likes Uber, Google, Gilead, Stan Druckenmiller Jun 12 2014 
Top 5 Hedge Fund Net Buys May 21 2014 
Weekly CFO Sells Highlight: Affiliated Managers Group Inc., Gilead Sciences Inc., L-3 Communications May 19 2014 
Competition From AbbVie Will Not Hurt Gilead Sciences Apr 27 2014 
Weekly Insider Sells Highlight: ATHN, GILD, JPM, WAG Apr 20 2014 

More From Our Partners
Earnings Scheduled For July 23, 2014 Jul 23 2014 - BENZINGA

More From Other Websites
Top Biotechnology Stocks Jul 23 2014
Gilead Earnings Preview: Non-Sovaldi Sales Bogey Of $2.94B May Be Unrealistic Jul 23 2014
Q2 2014 Gilead Sciences Earnings Release - 4:05 pm ET Jul 23 2014
This is What Happens When A New Drug Hits the Market and Nobody Knows What to Expect Jul 22 2014
[video] Earnings Preview: 3 Things to Watch Jul 22 2014
Gilead Sciences Should Report $4B In Sovaldi Sales In Q2'14 Jul 22 2014
Gilead's Pipeline Requires MacroGenics' ImmunoOncology Platform (M&A) Jul 22 2014
Alexion, 3 Other Top Biotechs Reporting Earnings Jul 22 2014
Gilead Expected to Post Sky-High Hep C Sales in June Quarter Jul 22 2014
HIV pills show more promise to prevent infection Jul 22 2014
Will Gilead (GILD) Earnings Disappoint in Q2 as Costs Rise? Jul 22 2014
Biogen Shares Rebound As Street Has A Change Of Heart Jul 21 2014
[video]Why I'm Shorting Gilead: Sentiment Is Too Positive Ahead of Earnings Jul 21 2014
[video] Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People Jul 21 2014
Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers Jul 21 2014
Gilead Sciences: Sovaldi's a Blockbuster, the Question is How Big Jul 21 2014
Gilead (GILD) Reaches New Lifetime High Today Jul 21 2014
How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding? Jul 21 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide